This CPB has been revised to state that the following are considered experimental and investigational: (I) evaluation of cortisol awakening response for the diagnosis of premenstrual syndrome (PMS) / premenstrual dysphoric disorder (PMDD); (ii) neuroimaging for the diagnosis of PMS / PMDD; and (iii) allopregnanolone antagonists (e.g., sepranolone) for the treatment PMS / PMDD.